2022
DOI: 10.1186/s12885-022-09514-3
|View full text |Cite
|
Sign up to set email alerts
|

Diagnostic value of tumor markers in identifying favorable or unfavorable subsets in patients with cancer of unknown primary: a retrospective study

Abstract: Background Routine measurement of tumor markers is not recommended in daily clinical practice for patients with cancer of unknown primary (CUP). We evaluated the diagnostic value of tumor markers in identifying favorable or unfavorable subsets in patients with CUP. Methods We retrospectively reviewed the medical records of patients who were diagnosed with CUP between October 2010 and July 2015 at the National Cancer Center Hospital. The tumor marke… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 26 publications
0
2
0
Order By: Relevance
“…In almost 70% of CUP patients, more than one marker can be concomitantly elevated in a non-specific way. Routine request of cancer antigen 125 (CA 125), cancer antigen 15.3 (CA 15-3), carbohydrate antigen 19-9 (CA 19-9), and carcinoembryonic antigen (CEA) is not recommended due to lack of prognostic and/or predictive value [ 59 ]. However, there are some clinical scenarios in which serum tumour markers may have some diagnostic value.…”
Section: Diagnostic Workupmentioning
confidence: 99%
“…In almost 70% of CUP patients, more than one marker can be concomitantly elevated in a non-specific way. Routine request of cancer antigen 125 (CA 125), cancer antigen 15.3 (CA 15-3), carbohydrate antigen 19-9 (CA 19-9), and carcinoembryonic antigen (CEA) is not recommended due to lack of prognostic and/or predictive value [ 59 ]. However, there are some clinical scenarios in which serum tumour markers may have some diagnostic value.…”
Section: Diagnostic Workupmentioning
confidence: 99%
“…Serum tumor markers can help clinicians analyze the disease; monitor efficacy, recurrence, and metastasis; and predict prognosis. However, multiple tumor markers are simultaneously elevated in a non-specific manner in nearly 70% of patients with CUP 7 , and specific tumor markers with prognostic and/or predictive value remain lacking. Beyond AFP (hepatocellular carcinoma), PSA (prostate cancer), and CA125 (ovarian cancer), which have relatively specific diagnostic value, other tumor markers must be comprehensively analyzed according to other clinical information from patients.…”
Section: Diagnosismentioning
confidence: 99%